Firefly Neuroscience (NASDAQ:AIFF) Trading 1.6% Higher – Still a Buy?

Firefly Neuroscience, Inc. (NASDAQ:AIFF)’s share price was up 1.6% during trading on Thursday . The company traded as high as $1.28 and last traded at $1.24. Approximately 71,266 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 146,945 shares. The stock had previously closed at $1.22.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AIFF. Weiss Ratings raised Firefly Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, May 19th. Wall Street Zen upgraded Firefly Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Firefly Neuroscience Price Performance

The company has a market capitalization of $17.95 million, a P/E ratio of -1.83 and a beta of 0.55. The firm’s 50-day moving average is $1.57 and its 200-day moving average is $1.44.

Firefly Neuroscience (NASDAQ:AIFF) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.13) earnings per share for the quarter. Firefly Neuroscience had a negative return on equity of 94.68% and a negative net margin of 565.40%.The business had revenue of $0.48 million for the quarter.

Hedge Funds Weigh In On Firefly Neuroscience

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC bought a new stake in Firefly Neuroscience during the fourth quarter valued at about $53,000. Geode Capital Management LLC increased its position in Firefly Neuroscience by 92.9% in the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock worth $341,000 after buying an additional 58,067 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Firefly Neuroscience by 393.3% in the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after buying an additional 401,085 shares during the period. 4.96% of the stock is currently owned by hedge funds and other institutional investors.

About Firefly Neuroscience

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.